Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alphaprodine is a synthetic opioid analgesic of the piperidine class that is chemically related to meperidine but has a more rapid onset and shorter duration of action. It acts primarily on the central nervous system (CNS) by binding to mu-opioid receptors, leading to analgesia as well as sedation and euphoria. Alphaprodine was first marketed in 1949 for use in labor and delivery, urologic procedures, minor surgical procedures, dental procedures, and as pre-operative medication. Its effects begin within minutes after intravenous administration and last about 1–2 hours. The drug is metabolized in the liver with excretion mainly via urine. Alphaprodine has a high potential for abuse and dependence similar to other opioids; it is classified as a Schedule II controlled substance in the United States[1][2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alphaprodine.